Phase 3 Recruiting Academic/Other
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head and neck reg…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06992427
Sites in New Jersey: - Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 3 Recruiting NIH
This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) a…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06589804
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Jefferson Cherry Hill Hospital — Cherry Hill, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Sidney Kimmel Cancer Center Washington Township — Sewell, New Jersey
Phase 2, Phase 3 Recruiting Academic/Other
This phase II/III trial studies how well sentinel lymph node biopsy works and compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer. Sentinel lymph node biopsy s…
Sponsor: NRG Oncology
NCT ID: NCT04333537
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Sites in New Jersey: - Research Site — Camden, New Jersey
- Research Site — East Brunswick, New Jersey
- Research Site — Hackensack, New Jersey
- Research Site — New Brunswick, New Jersey
- Research Site — Summit, New Jersey
Phase 3 Recruiting Industry
This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
Sponsor: Merus B.V.
NCT ID: NCT06525220
Sites in New Jersey: - Site 94 — Hackensack, New Jersey
Phase 3 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…
Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Sites in New Jersey: - Morristown Medical Center — Morristown, New Jersey
Phase 2 Recruiting Network
This phase II trial studies how well radiation therapy with or without cisplatin works in treating patients with stage III-IVA squamous cell carcinoma of the head and neck who have undergone surgery. Radiation therapy uses high energy x-ra…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT02734537
Sites in New Jersey: - Jersey City Medical Center — Jersey City, New Jersey
- Saint Barnabas Medical Center — Livingston, New Jersey
- Monmouth Medical Center — Long Branch, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 2 Recruiting NIH
This phase II trial tests effects of nivolumab in combination with chemotherapy drugs prior to radiation therapy patients with nasopharyngeal carcinoma (NPC). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06064097
Sites in New Jersey: - Hackensack University Medical Center — Hackensack, New Jersey
- Jersey Shore Medical Center — Neptune City, New Jersey
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital — New Brunswick, New Jersey
- Newark Beth Israel Medical Center — Newark, New Jersey
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a fi…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT04895709
Sites in New Jersey: - John Theurer Cancer Center — Hackensack, New Jersey
Phase 2 Recruiting Academic/Other
This study will test whether limiting standard photon intensity modulated radiation therapy (IMRT) to exclude the oral tongue surgical site can decrease the risk of side effects caused by oral radiation. The researchers will also find out …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06485778
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs …
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT05491512
Sites in New Jersey: - Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
This clinical trial studies the effect of customized 3 dimensional (3D) printed oral tents on patients with head and neck cancer who are receiving radiotherapy. Oral stents are made from the impression of patients' mouth and cover patients…
Sponsor: M.D. Anderson Cancer Center
NCT ID: NCT04870762
Sites in New Jersey: - Cooper Hospital University Medical Center — Camden, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study to find out if the combination of avutometinib and defactinib is an effective treatment for RAF dimer-driven radioiodine-refractory differentiated thyroid cancer or anaplastic thyroid cancer. The resear…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06007924
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 2 Recruiting Academic/Other
The researchers are doing this study is to find out if lower doses (given in fewer treatments over a shorter period of time) of radiation therapy in combination with standard-of-care chemotherapy is an effective treatment for people with H…
Sponsor: Memorial Sloan Kettering Cancer Center
NCT ID: NCT06984861
Sites in New Jersey: - Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale, New Jersey
Phase 1, Phase 2 Recruiting Industry
This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tum…
Sponsor: InduPro, Inc.
NCT ID: NCT07602842
Sites in New Jersey: - Hackensack Meridian - John Theurer Cancer Center — Edison, New Jersey
Phase 2 Recruiting Academic/Other
This is a phase II clinical trial to assess the clinical activity of immunotherapy with E7 TCR-T cells for metastatic HPV-associated cancers. HPV-associated cancers in include cervical, throat, penile, vulvar, vaginal, anal, and other canc…
Sponsor: Christian Hinrichs
NCT ID: NCT05686226
Sites in New Jersey: - Rutgers Cancer Institute — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
Phase 1, Phase 2 Recruiting Academic/Other
The goal of this study is to determine the feasibility of administration of a single dose of E7 TCR-T cells as induction therapy prior to definitive treatment (chemoradiation or surgery) of locoregionally advanced HPV-associated cancers. T…
Sponsor: Christian Hinrichs
NCT ID: NCT05639972
Sites in New Jersey: - Rutgers Cancer Institute — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn the safety and effects of the study medicine (PF-07799544) alone or in combination as a potential cancer treatment for adults with advanced solid tumors. The study will be conducted in two par…
Sponsor: Pfizer
NCT ID: NCT05538130
Sites in New Jersey: - MSK Basking Ridge. — Basking Ridge, New Jersey
- MSK Monmouth. — Middletown, New Jersey
- MSK Bergen. — Montvale, New Jersey
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in New Jersey: - Exelixis Clinical Site #88 — East Brunswick, New Jersey
- Exelixis Clinical Site #105 — Hackensack, New Jersey
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
Phase 1 Recruiting Industry
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines in people with solid tumors. This study is …
Sponsor: Pfizer
NCT ID: NCT05355701
Sites in New Jersey: - MSK Monmouth — Middletown, New Jersey
Phase 1 Recruiting NIH
This phase I/Ib trial tests the safety and best dose of ipatasertib in combination with the usual treatment approach using chemotherapy together with radiation therapy ("chemo-radiation") in patients with head and neck cancer. Ipatasertib …
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05172245
Sites in New Jersey: - Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
- Rutgers New Jersey Medical School — Newark, New Jersey
Phase 1 Recruiting Academic/Other
This is a phase I clinical trial to determine the maximum tolerated dose (MTD) of KK-LC-1 TCR-T cells for the treatment of metastatic cancers that express KK-LC-1. Participants will receive a conditioning regimen, KK-LC-1 TCR-T cells, and …
Sponsor: Christian Hinrichs
NCT ID: NCT05483491
Sites in New Jersey: - Rutgers Cancer Institute — New Brunswick, New Jersey
- RWJBarnabas Health - Robert Wood Johnson University Hospital — New Brunswick, New Jersey
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in New Jersey: - Englewood Hospital and Medical Center — Englewood, New Jersey
- CentraState Medical Center — Freehold, New Jersey
- Hackettstown Medical Center — Hackettstown, New Jersey
- Morristown Medical Center — Morristown, New Jersey
- Inspira Medical Center Mullica Hill — Mullica Hill, New Jersey
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in New Jersey: - Massive Bio SYNERGY-AI site — New Brunswick, New Jersey